TG Therapeutics (TGTX) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for TG Therapeutics (NASDAQ: TGTX):

• 12/15/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/14/2025 – TG Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/8/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – TG Therapeutics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/1/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – TG Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/4/2025 – TG Therapeutics was upgraded by analysts at B. Riley to a “strong-buy” rating.
• 11/3/2025 – TG Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.64% of the company’s stock.

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.